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Introduction
As once famously noted by former US 
surgeon-general, C Everett Koop, “Drugs 
don’t work in patients who don’t take 
them”.1 Indeed over the last four decades, 
researchers and clinicians alike have 
arrived at the understanding that patient 
adherence to clinically appropriate therapies 
is fundamental to positive therapeutic 
outcomes.2 However, it has been well 
documented that patients do not necessarily 
take their medications as prescribed, or 
even at all in some cases, with symptomatic 
deterioration or medical exacerbations often 
ensuing as a consequence.2 Non-adherence 
not only affects the patients themselves, 
but it also contributes to increased societal 
disease burden and healthcare costs.2
When presented with estimates that 50% 
of chronic disease patients are not adherent 
to their prescribed treatment regimens2, 
it is clear to see why the field of patient 
adherence has become the focus of much 
interest in the literature. There is particular 
interest amongst researchers to identify 
the factors that contribute to treatment 
non-adherence and develop strategies to 
tackle these.3 The purpose of this article is 
to provide an overview of research exploring 
the impact of gender on treatment adherence 
across a few key chronic disease states. 
It is important to note that to our 
knowledge, few studies have been conducted 
to explore this specific relationship as 
a primary research aim, rather the vast 
majority touch on the link between 
gender and adherence in a secondary or 
even incidental fashion. Nevertheless, 
these studies do shed some light onto the 
complicated quagmire that is treatment 
non-adherence and may ultimately provide 
clinicians and researchers with insight into 
potential gender-related differences in 
adherence regarding specific disease states. 
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•	 To briefly explore the findings of studies relating to the impact of gender on treatment 
adherence
•	 To provide insight into how the findings of such studies should be interpreted and their 
potential value.
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Abstract
Non-adherence to prescribed medications has been the focus of much 
interest in the literature owing to the poor treatment outcomes and 
increased healthcare burden which ensue as a consequence. In order 
to develop targeted interventions to address treatment non-adherence, 
it is necessary to first understand the factors which may influence 
patients’ medication taking behaviour. It has been suggested that 
patient gender may be one such factor, where knowledge of its 
impact can have the potential to assist researchers and clinicians 
in pre-empting instances of non-adherence and allowing them to 
monitor patients more closely and intervene in a timely fashion if 
required. In this article, we explore the issue of gender and non-
adherence by examining the findings of studies related to three key 
disease states. It is apparent that there are variations in research 
evidence on this topic and that it is likely that other factors such as 
regimen complexity and patient knowledge interplay and may also 
demonstrate a larger role in impacting adherence to therapy.
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Asthma
Studies exploring the relationship between 
gender and adherence to asthma treatment 
have provided mixed results. 
Despite having a greater number of visits 
with their physicians and a higher likelihood 
of possessing an asthma action plan,4 female 
asthma patients have been shown in some 
studies to have poorer adherence to asthma 
medications than males.5-7 In the study 
by Williams et al5 adherence to inhaled 
corticosteroids (ICS) was measured by linking 
prescription refill information with patients’ 
prescribed dosing information. The authors 
discovered that female asthma patients had 
significantly lower adherence to ICS than 
males. Similar findings were found in a study 
by Chatkin et al6 who counted the number 
of dry powder inhaler doses remaining after 
90 days to determine patient adherence. 
Patients who had used ≥85% of their 
prescribed doses were considered adherent. 
Lower rates of adherence were observed 
amongst female patients (46.3%) compared 
to males (65.8%) although this was not a 
statistically significant difference. 
While these results may point towards 
an increased likelihood of non-adherence 
amongst females, this is not necessarily 
true in all instances. To the contrary, the 
findings of a qualitative study exploring 
the factors influencing adherence amongst 
asthma patients highlighted that female 
gender was a significant factor with respect 
to medicine-taking.8 This was even the case 
for asthmatic patients who were experiencing 
exacerbations, as shown in another study 
utilising self-reported adherence measures.9 
In this study, females were more adherent 
than males during maintenance treatment of 
asthma and significantly so during episodes 
of exacerbations.9
Although these findings may suggest 
that the literature regarding gender and 
adherence in asthma falls under one of two 
categories, it is important to recognise that 
there are in fact numerous studies which 
have failed to find any significance to this 
relationship altogether.4,10,11 
Diabetes
As with the asthma-related research, studies 
exploring the relationship between gender 
and adherence in patients with diabetes are 
also discordant. 
Wong et al12 conducted a large cohort 
study, using prescription data to determine 
patients’ level of adherence to oral 
hypoglycaemic agents using the medication 
possession ratio (MPR). The MPR is the ratio 
of the total days’ supply of medication to 
the total number of days in a defined time 
period,13 with values ≥80% indicating an 
adequate level of adherence.14 In utilising 
this metric, the researchers highlighted that 
male patients were significantly less likely to 
adhere to their prescribed treatments than 
females. 
This is in contrast with the findings of 
two other retrospective cohort studies.15,16 
Also using MPR to estimate adherence to 
antihyperglycemic medications. Hertz et 
al15 highlighted that females had poorer 
adherence than their male counterparts and 
that the female gender was a risk factor for 
non-persistence with treatment. This was 
also the case in the study by Egede et al16, 
which supported the finding that males had 
higher MPR levels than females. Female 
gender was also identified as a predictor of 
treatment non-adherence in a prospective 
cohort study of patients with type 2 diabetes 
receiving insulin therapy.17
Depression
Not surprisingly, inconsistencies also exist 
amongst research relating to gender and 
adherence to antidepressant medications. 
In their review of the literature related 
to factors influencing antidepressant 
medication adherence, van Servellen et 
al18 reported that no associations could 
be conclusively made between gender and 
its impact on patient adherence. Similarly, 
Bogner et al19 determined that there was no 
relationship between gender and adherence 
to the antidepressant citalopram in their 
prospective study where pill counts were 
used to determine patients’ adherence 
levels. However, a study by Granger et 
al20 highlighted that females were twice 
as likely as males to be non-adherent to 
bupropion therapy as determined by the 
results of a 20-item web based survey of 
527 patients on this treatment. 
There is a body of literature however, 
which provides evidence to suggest that 
female patients are more adherent to 
antidepressant medications than males.21-23 
In the retrospective study of a medical 
claims database by Crown et al21, it was 
determined that female gender was 
associated with a statistically significant 
higher probability of filling consecutive 
prescriptions for antidepressants. Using 
data from a health administration 
database, Pfeiffer et al22 were also able 
to demonstrate a significant relationship 
between gender and antidepressant 
medication adherence, revealing that 
females were significantly more likely to 
have adequate adherence. Furthermore, in 
their cross-sectional prospective study of 
patients taking antidepressant medications 
Roca et al23 identified that males were 
significantly more likely to have poor 
adherence. 
Closing remarks and conclusions
In light of the findings presented in 
this article, it becomes clear why the 
relationship between gender and adherence 
has not been explored in depth in the 
research literature. While there is evidence 
to suggest that males and females 
have different healthcare attitudes and 
behaviours,24,25 it would appear that with 
regards to treatment adherence specifically, 
Key points
•	 Non-adherence to clinically appropriate treatments is associated with symptomatic 
deterioration, increased societal disease burden and healthcare costs.
•	 Patients’ non-adherence to prescribed treatments has become the focus of much 
interest in the literature.
•	 Many factors contributing to treatment non-adherence have been explored in the 
literature, although the influence of patient gender on treatment adherence has 
been explored in a secondary or incidental fashion. 
•	 Some studies of adherence to treatment for prevalent chronic conditions have 
highlighted that females are more adherent than males, while others have revealed 
the opposite effect. 
•	 While gender may contribute to treatment non-adherence in some cases, it is likely 
that other factors such as regimen complexity and patient knowledge play a larger 
role in impacting adherence to therapy.
•	 It is important to consider the findings of these studies alongside those of studies 
investigating potential factors contributing to non-adherence more broadly.  
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there may be more pertinent and influential 
factors than gender that come into play. 
The complexity of the field of treatment 
adherence must be acknowledged and as 
such, it would be almost impossible to 
explain the behaviours associated with this 
phenomenon simply as a function of patient 
gender. It would be more appropriate to 
recommend that researchers and clinicians 
consider these non-modifiable factors such 
as gender or ethnicity within a broader 
context of factors that may contribute to 
patients’ medication-taking behaviours. 
These include but are not limited to the 
complexity of the treatment regimen, patient 
education and socioeconomic status and 
access to appropriate illness and treatment-
related information.26 
In saying this, it is not our intention 
to discount the findings of the studies 
included in this article. In some instances, 
the studies included here have heralded the 
superiority of one gender over the other 
in their adherence to treatment regimens. 
This may provide clinicians with some level 
of insight into potential cases of treatment 
inefficacy that they may come across. 
However, it is important to acknowledge that 
it is difficult to compare study findings in 
this area owing to differences in their aims, 
methods, populations studied and definitions 
of adherence. As such, these study findings 
should be considered in conjunction with 
the findings of studies approaching this 
topic from a broader perspective, in order 
to provide strength and relevance to their 
conclusions and their applicability to real-
world clinical settings. 
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